These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26435643)

  • 1. Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.
    Chondros Κ; Karpathakis Ν; Heretis Ι; Mavromanolakis Ε; Chondros N; Sofras F; Mamoulakis C
    Hippokratia; 2015; 19(1):30-3. PubMed ID: 26435643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive criteria of insignificant prostate cancer: what is the correspondence of linear extent to percentage of cancer in a single core?
    Billis A; Quintal MM; Freitas LL; Costa LB; Ferreira U
    Int Braz J Urol; 2015; 41(2):367-72. PubMed ID: 26005981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
    Carter HB; Sauvageot J; Walsh PC; Epstein JI
    J Urol; 1997 Jun; 157(6):2206-9. PubMed ID: 9146616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
    Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
    BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know.
    Rubio-Briones J; Iborra I; Ramírez M; Calatrava A; Collado A; Casanova J; Domínguez-Escrig J; Gómez-Ferrer A; Ricós JV; Monrós JL; Dumont R; López-Guerrero JA; Salas D; Solsona E
    Actas Urol Esp; 2014 Nov; 38(9):559-65. PubMed ID: 24636075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perineural invasion and TRUS findings are complementary in predicting prostate cancer biology.
    Martinez CH; Williams AK; Chin JL; Stitt L; Izawa JI
    Can J Urol; 2013 Apr; 20(2):6696-701. PubMed ID: 23587509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of radical prostatectomy in patients meeting criteria for active surveillance.
    Dellavedova T; Ponzano RM; Sarria JP; Minuzzi PG; Nobile RH; Minuzzi FG
    Arch Esp Urol; 2013 May; 66(4):342-9. PubMed ID: 23676537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
    Epstein JI; Chan DW; Sokoll LJ; Walsh PC; Cox JL; Rittenhouse H; Wolfert R; Carter HB
    J Urol; 1998 Dec; 160(6 Pt 2):2407-11. PubMed ID: 9817393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
    Epstein JI; Walsh PC; Brendler CB
    J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
    Allan RW; Sanderson H; Epstein JI
    J Urol; 2003 Aug; 170(2 Pt 1):370-2. PubMed ID: 12853777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
    Epstein JI; Walsh PC; Carmichael M; Brendler CB
    JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
    Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
    Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
    Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
    Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redefining the Concept of Clinically Insignificant Prostate Cancer.
    Frankcombe DE; Li J; Cohen RJ
    Urology; 2020 Feb; 136():176-179. PubMed ID: 31715271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
    Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer.
    Furuya Y; Fuse H; Nagakawa O; Masai M
    Int J Clin Oncol; 2002 Apr; 7(2):109-13. PubMed ID: 12018107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.